Paradigm Biopharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
So good morning, good afternoon, everyone. By way of introduction, my name is Jonathan Schwartz, and I'm the head of JPMorgan's healthcare investment banking team here in Australia. It's my great pleasure to welcome Paradigm Biopharmaceuticals to the 2021 JPMorgan Healthcare Conference.
With us today is Paul Rennie, the CEO of Paradigm. And with that, I'll hand over to Paul to take us through his presentation.
Thank you very much, Seth. And also, thank you very much to the JPMorgan network for the opportunity to make a presentation to this healthcare conference. Next slide, please.
So I'm on slide 2. And as Seth said, I'm the Founder and Chief Executive Officer of Paradigm Biopharmaceuticals. And I would like to start off by saying that I have been searching for the holy grail for osteoarthritis treatment, especially for moderate-to-severe osteoarthritis for the best part of 20 years.
I've had lots of experience
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |